Board of Directors
Board of Directors
Rear Admiral [Ret] James J. Carey
Rear Admiral [Ret.] James J. Carey has a proven background of senior leadership in the American military, the U.S. federal government, the private sector, and the philanthropic world. He is the former Chairman of the U. S. Federal Maritime Commission during the administrations of President Reagan and President George Bush Sr. He retired from the American Navy in 1994 following service on the staff of the Chief of Naval Operations. He has been a member of 30+ boards of directors during his various careers, and has been the elected National Chairman of five national/international organizations or associations. He currently serves as Chairman of the Admiral Carey Foundation and is also the elected National Chairman of The Flag & General Officers' Network, a 3000+ member organization of U.S. admirals and generals. Admiral Carey brings to our Pivotal board of directors a wealth of experience, qualifications, and leadership with the U.S. federal government, the U. S. Department of Defense, the private sector and corporate world, and a broad range of associations and organizations of significant value to our Pivotal business plan. He lives in Alexandria, VA, USA.
Giuseppe Simeone
Bringing a science and strong finance background to this role, Mr. Simeone's expertise is considered a vital asset for Pivotal Therapeutics. A graduate of York University with a Bachelor of Sciences degree and a career in commercial finance and business in the banking and construction industries, Mr. Simeone has held various positions in the lending field. Most notably, as Manager of Finance of York Steel Construction, and executive vice-president of Global Travel Solutions, a family business. Mr. Simeone grew the business from $3 million to $175 million continuing to work with the company until its sale in 2000.
John Gebhardt, DBA
Mr. Gebhardt has an extensive background in the investment securities business including retail and institutional sales, primary market making, marketing, and product management, with thirty years experience at the executive level. He has a track record of excellence, guiding departments to consistent profitability, through strategic and often innovative management of marketing and sales efforts. He spent over twenty years with Paine Webber, retiring as a Managing Director. While at Paine Webber, Mr. Gebhardt originated Electronically Monitored Stop Orders in the NASDAQ market, which still serves as the industry standard. As a Managing Director at Knight Capital Group, Mr. Gebhardt originated their Listed Block Desk, guiding it to a top industry ranking. Mr. Gebhardt's expertise in equity trading, regulatory compliance, and product development adds great value to the Pivotal Therapeutics team. Mr. Gebhardt studied economics and psychology at New York University's, Stern School of Business and at Pace University's, Lubin School of Business.
George Jackowski, Ph.D
Chairman, Chief Scientific Officer
Dr. Jackowski has been instrumental in the founding of nine biotechnology companies in his career, four of which are public. Furthermore, he has contributed to the creation of 12 additional biotechnology companies. He has grown companies to market caps of over $350 million, raised from public capital markets over $125 million and completed deals with Big Pharma of over $100 million USD in transactions. His most recent experience is as Chairman, CEO and CSO of SynX Pharma Inc., which he founded in 1997 and was acquired by Nanogen Inc., a San Diego based company. Dr. Jackowski holds Directorships in numerous biotech companies. Dr. Jackowski holds academic positions at the University of Toronto in the Department of Laboratory Medicine and Pathobiology and the Department of Surgery. He also served in the past as the Chairman of Bio Canada Connect, was a Board Member of the Ontario BIOCouncil and on the Board of Directors for the Canadian Stroke Network. His scientific resume includes authoring 44 publications and 61 abstracts, holding over 136 patents filed and issued, and receiving the 1996 MEDEC Award for Medical Achievement for his invention of the Cardiac STATUS™ CK-MB/Myoglobin Card Test, which aids in the early diagnosis of myocardial infarction and is commercialized worldwide in hospital emergency rooms. Dr. Jackowski has also served on many federal and provincial governmental biotechnology committees. Dr. Jackowski has been intimately involved in the enforcement of patent claims, patent litigation and patent interference proceedings. Dr. Jackowski, a respected cardiovascular biochemist, received his training at the Cardiovascular Research Institute at the University of San Francisco, California. Dr. Jackowski has over 25 years experience and extensive networks in the cardiovascular and CNS disease markets, particularly pertaining to the commercialization of diagnostic products.
